CheckMate 214 patient-reported outcomes: listening to our patients

Affiliations

¹ Division of Oncology, Policlinico Sant'Orsola-Malpighi Hospital, Bologna 40138, Italy. Electronic address: fmassari79@gmail.com.
² Division of Oncology, Policlinico Sant'Orsola-Malpighi Hospital, Bologna 40138, Italy.

Comment

Francesco Massari et al. Lancet Oncol. 2019 Feb.

. 2019 Feb;20(2):179-180.

doi: 10.1016/S1470-2045(18)30790-3. Epub 2019 Jan 15.

¹ Division of Oncology, Policlinico Sant'Orsola-Malpighi Hospital, Bologna 40138, Italy. Electronic address: fmassari79@gmail.com.
² Division of Oncology, Policlinico Sant'Orsola-Malpighi Hospital, Bologna 40138, Italy.

Erratum in

Correction to Lancet Oncol 2019; 20: 179-80.
[No authors listed] [No authors listed] Lancet Oncol. 2019 Feb;20(2):e72. doi: 10.1016/S1470-2045(19)30017-8. Lancet Oncol. 2019. PMID: 30712807 No abstract available.

No abstract available

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D, Grünwald V, Escudier B, Hammers HJ, George S, Nathan P, Grimm MO, Rini BI, Doan J, Ivanescu C, Paty J, Mekan S, Motzer RJ. Cella D, et al. Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15. Lancet Oncol. 2019. PMID: 30658932 Free PMC article. Clinical Trial.